Gilead Sciences’ seladelpar has been recommended by the European Medicines Agency’s human medicines committee to treat the ...

In addition to Europe, Gilead is working with regulatory authorities on marketing applications for seladelpar in other parts of the world. In August 2024, the FDA granted accelerated approval for ...

Gilead Sciences is just a few weeks away from an FDA decision on seladelpar for rare liver disease primary biliary cholangitis (PBC) and will be buoyed by new data pointing to its long-term ...

Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...

Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.

(RTTNews) - Gilead Sciences, Inc. (GILD ... adopted a positive opinion recommending seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid ...

Gilead (GILD) Sciences announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending seladelpar for the treatment of ...

CloseCurlyDoubleQuote; In addition to Europe, Gilead is working with regulatory authorities on marketing applications for seladelpar in other parts of the world. In August 2024, the FDA granted ...

Seladelpar Would Provide an Important Treatment Option for People Living with the Rare Liver Disease in the EU – FOSTER CITY, Calif., December 13, 2024--(BUSINESS WIRE)--Gilead Sciences ...